Age-related macular degeneration is the most common cause of vision loss in adults over age 50, but there are few treatments available. Researchers are now developing promising stem cell therapies to treat the disease.
Between invasive surgery or risky laser therapy, people suffering from severe eye floaters have no great treatment options. Now, with the development of a safer and less invasive nanoparticle-based therapy, people with floaters may finally get their vision and quality of life back.
Roche's faricimab injected every 16 weeks proves non-inferior to aflibercept injected every eight weeks in patients with “wet” age-related macular degeneration
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.